Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: hautnah 4/2015

01.11.2015 | Atopische Dermatitis

Ein Silberstreif am Horizont – was ist in der Pipeline an neuen Wirkstoffen bei atopischer Dermatitis?

verfasst von: Dr. Christine Bangert

Erschienen in: hautnah | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Zusammenfassung

Immunsuppressive systemische Medikamente zur Behandlung der schweren, therapierefraktären atopischen Dermatitis (AD) sind häufig aufgrund der teils stark ausgeprägten Nebenwirkungen in ihrer Anwendung limitiert. Eine gut verträgliche und wirksame Alternative für die Therapie von Patienten mit schwer ausgeprägter AD im Kindes- und Erwachsenenalter ist dringend notwendig. Biologika blockieren gezielt einen für die Krankheitsentstehung relevanten Botenstoff und werden bereits erfolgreich in der Therapie der Psoriasis eingesetzt. Obwohl derzeit noch kein Biologikum für die Behandlung der AD zugelassen ist, stellen sie vielversprechende Medikamente dar, die zukünftig in der Therapie des Ekzems schwer betroffener Patienten eine Rolle spielen könnten. In diesem Artikel wird ein Überblick über die möglichen zukünftigen Therapiemodalitäten der atopischen Dermatitis gegeben und gleichzeitig ihre Wirksamkeit bei AD diskutiert.
Literatur
2.
Zurück zum Zitat Eichenfield LF et al (2014) Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol 70(2):338–351 PubMedCentralCrossRefPubMed Eichenfield LF et al (2014) Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol 70(2):338–351 PubMedCentralCrossRefPubMed
3.
Zurück zum Zitat Eyerich K, Novak N (2013) Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy 68(8):974–982 CrossRefPubMed Eyerich K, Novak N (2013) Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy 68(8):974–982 CrossRefPubMed
4.
Zurück zum Zitat Gittler JK et al (2012) Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol 130(6):1344–1354 PubMedCentralCrossRefPubMed Gittler JK et al (2012) Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol 130(6):1344–1354 PubMedCentralCrossRefPubMed
5.
Zurück zum Zitat Werfel T et al (2009) Atopic dermatitis: S 2 guidelines. J Dtsch Dermatol Ges 7(Suppl 1):1–46 CrossRef Werfel T et al (2009) Atopic dermatitis: S 2 guidelines. J Dtsch Dermatol Ges 7(Suppl 1):1–46 CrossRef
6.
Zurück zum Zitat Eichenfield LF et al (2014) Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 71(1):116–132 PubMedCentralCrossRefPubMed Eichenfield LF et al (2014) Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 71(1):116–132 PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Sidbury R et al (2014) Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol 71(2):327–349 PubMedCentralCrossRefPubMed Sidbury R et al (2014) Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol 71(2):327–349 PubMedCentralCrossRefPubMed
8.
Zurück zum Zitat Guttman-Yassky E, Dhingra N, Leung DY (2013) New era of biologic therapeutics in atopic dermatitis. Expert Opin Biol Ther 13(4):549–561 CrossRefPubMed Guttman-Yassky E, Dhingra N, Leung DY (2013) New era of biologic therapeutics in atopic dermatitis. Expert Opin Biol Ther 13(4):549–561 CrossRefPubMed
9.
Zurück zum Zitat Novak N et al (2011) Subcutaneous immunotherapy with a depigmented polymerized birch pollen extract – a new therapeutic option for patients with atopic dermatitis. Int Arch Allergy Immunol 155(3):252–256 CrossRefPubMed Novak N et al (2011) Subcutaneous immunotherapy with a depigmented polymerized birch pollen extract – a new therapeutic option for patients with atopic dermatitis. Int Arch Allergy Immunol 155(3):252–256 CrossRefPubMed
10.
Zurück zum Zitat Werfel T et al (2006) Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy 61(2):202–205 CrossRefPubMed Werfel T et al (2006) Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy 61(2):202–205 CrossRefPubMed
11.
Zurück zum Zitat Novak N et al (2012) Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. J Allergy Clin Immunol 130(4):925–931e4 CrossRefPubMed Novak N et al (2012) Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. J Allergy Clin Immunol 130(4):925–931e4 CrossRefPubMed
12.
Zurück zum Zitat Buddenkotte J, Steinhoff M (2010) Pathophysiology and therapy of pruritus in allergic and atopic diseases. Allergy 65(7):805–821 CrossRefPubMed Buddenkotte J, Steinhoff M (2010) Pathophysiology and therapy of pruritus in allergic and atopic diseases. Allergy 65(7):805–821 CrossRefPubMed
13.
Zurück zum Zitat Thomsen JS et al (2002) Experimental itch in sodium lauryl sulphate-inflamed and normal skin in humans: a randomized, double-blind, placebo-controlled study of histamine and other inducers of itch. Br J Dermatol 146(5):792–800 CrossRefPubMed Thomsen JS et al (2002) Experimental itch in sodium lauryl sulphate-inflamed and normal skin in humans: a randomized, double-blind, placebo-controlled study of histamine and other inducers of itch. Br J Dermatol 146(5):792–800 CrossRefPubMed
14.
Zurück zum Zitat Sonkoly E et al (2006) IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 117(2):411–417 CrossRefPubMed Sonkoly E et al (2006) IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 117(2):411–417 CrossRefPubMed
15.
Zurück zum Zitat Roosterman D et al (2006) Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. Physiol Rev 86(4):1309–1379 CrossRefPubMed Roosterman D et al (2006) Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. Physiol Rev 86(4):1309–1379 CrossRefPubMed
16.
Zurück zum Zitat Beck LA et al (2014) Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371(2):130–139 CrossRefPubMed Beck LA et al (2014) Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371(2):130–139 CrossRefPubMed
17.
Zurück zum Zitat Fernandez-Anton Martinez MC et al (2014) Ustekinumab in the treatment of severe atopic dermatitis: a preliminary report of our experience with 4 patients. Actas Dermosifiliogr 105(3):312–313 CrossRefPubMed Fernandez-Anton Martinez MC et al (2014) Ustekinumab in the treatment of severe atopic dermatitis: a preliminary report of our experience with 4 patients. Actas Dermosifiliogr 105(3):312–313 CrossRefPubMed
18.
Zurück zum Zitat Soumelis V et al (2002) Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 3(7):673–680 PubMed Soumelis V et al (2002) Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 3(7):673–680 PubMed
19.
Zurück zum Zitat Nograles KE et al (2009) IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol 123(6):1244–1252e2 PubMedCentralCrossRefPubMed Nograles KE et al (2009) IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol 123(6):1244–1252e2 PubMedCentralCrossRefPubMed
20.
Zurück zum Zitat Simon D et al (2008) Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 121(1):122–128 CrossRefPubMed Simon D et al (2008) Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 121(1):122–128 CrossRefPubMed
21.
Zurück zum Zitat Sediva A et al (2008) Anti-CD20 (rituximab) treatment for atopic eczema. J Allergy Clin Immunol 121(6):1515–1516; author reply 1516–1517 CrossRefPubMed Sediva A et al (2008) Anti-CD20 (rituximab) treatment for atopic eczema. J Allergy Clin Immunol 121(6):1515–1516; author reply 1516–1517 CrossRefPubMed
22.
Zurück zum Zitat Heil PM et al (2010) Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course – a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges 8(12):990–998 PubMed Heil PM et al (2010) Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course – a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges 8(12):990–998 PubMed
23.
Zurück zum Zitat Vigo PG et al (2006) Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 55(1):168–170 CrossRefPubMed Vigo PG et al (2006) Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 55(1):168–170 CrossRefPubMed
24.
Zurück zum Zitat Turner PJ et al (2012) Intravenous immunoglobulin to treat severe atopic dermatitis in children: a case series. Pediatr Dermatol 29(2):177–181 CrossRefPubMed Turner PJ et al (2012) Intravenous immunoglobulin to treat severe atopic dermatitis in children: a case series. Pediatr Dermatol 29(2):177–181 CrossRefPubMed
25.
Zurück zum Zitat Paul C et al (2002) A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis. Br J Dermatol 147(3):518–522 CrossRefPubMed Paul C et al (2002) A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis. Br J Dermatol 147(3):518–522 CrossRefPubMed
26.
Zurück zum Zitat Jee SJ et al (2011) Long-term efficacy of intravenous immunoglobulin therapy for moderate to severe childhood atopic dermatitis. Allergy Asthma Immunol Res 3(2):89–95 PubMedCentralCrossRefPubMed Jee SJ et al (2011) Long-term efficacy of intravenous immunoglobulin therapy for moderate to severe childhood atopic dermatitis. Allergy Asthma Immunol Res 3(2):89–95 PubMedCentralCrossRefPubMed
27.
Zurück zum Zitat Navarini AA, French LE, Hofbauer GF (2011) Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial superinfection. J Allergy Clin Immunol 128(5):1128–1130 CrossRefPubMed Navarini AA, French LE, Hofbauer GF (2011) Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial superinfection. J Allergy Clin Immunol 128(5):1128–1130 CrossRefPubMed
28.
Zurück zum Zitat Jacobi A et al (2005) Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 52(3 Pt 1):522–526 CrossRefPubMed Jacobi A et al (2005) Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 52(3 Pt 1):522–526 CrossRefPubMed
Metadaten
Titel
Ein Silberstreif am Horizont – was ist in der Pipeline an neuen Wirkstoffen bei atopischer Dermatitis?
verfasst von
Dr. Christine Bangert
Publikationsdatum
01.11.2015
Verlag
Springer Vienna
Erschienen in
hautnah / Ausgabe 4/2015
Print ISSN: 1866-2250
Elektronische ISSN: 2192-6484
DOI
https://doi.org/10.1007/s12326-014-0144-y